TriSalus Life Sciences (TLSI) Operating Income (2021 - 2026)

TriSalus Life Sciences has reported Operating Income for 6 years, with the latest figure at -$8.4 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Income fell 14.76% year-over-year to -$8.4 million; the trailing twelve-month figure through Mar 2026 stood at -$28.0 million (up 11.92% YoY), and the FY2025 full-year result was -$26.9 million, up 25.49% from the prior year.
• Operating Income for Q1 2026 stood at -$8.4 million, down from -$3.3 million in the prior quarter.
• The five-year high for Operating Income was -$288273.0 in Q2 2022, with the low at -$18.6 million in Q3 2023.
• Historically, Operating Income has averaged -$8.6 million across 5 years, with a median of -$8.4 million in 2026.
• Annual changes were most pronounced in 2022 — Operating Income jumped 63.23% — and 2023, when it slumped 3866.38%.
• TriSalus Life Sciences' Operating Income stood at -$11.8 million in 2022, then declined by 21.03% to -$14.2 million in 2023, then jumped by 46.8% to -$7.6 million in 2024, then soared by 56.85% to -$3.3 million in 2025, then plunged by 157.14% to -$8.4 million in 2026.
• The last three Operating Income figures came in at -$8.4 million (Q1 2026), -$3.3 million (Q4 2025), and -$9.0 million (Q3 2025), per Business Quant data.